Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons

Journal of Neurochemistry

Volumn 67, Issue 5, 1996, Pages 2164-2171

  Andersen, J K ^a   Mo, J Q ^a   Horn, D G ^a   Lee, F Y ^b   Harnish, P ^b   Hamill, R W ^c   McNeill, T H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Aging; Buthionine sulfoximine; Cellular metabolism; Glutathione; Neuronal cell damage; Oxidative stress

Indexed keywords

BUTHIONINE SULFOXIMINE; DOPAMINE; GLUTATHIONE; LIPOFUSCIN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL METABOLISM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; LIPID PEROXIDATION; MALE; MOUSE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALIA; MURINAE; RODENTIA;

EID: 0029845402     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.67052164.x     Document Type: Article

References (45)

1. Andersen J. K., Frim D. M., Isacson O., and Breakefield X. O. (1994) Catecholaminergic cell atrophy in a transgenic mouse aberrantly overexpressing MAO-B in neurons. Neurodegeneration 3, 97-109.
2. Bannon M. J., Goedert M., and Wolff O. H. (1984) The possible relationship of glutathione, melanin, and 1-methyl-4-pnenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem. Pharmacol. 33, 2697-2698.
3. Beal F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
4. Ben-Shachar D., Eschel G., Riederer P., and Youdim M. B. H. (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implications for Parkinson's disease. Ann. Neurol. 32 (Suppl.), S105-S110.
5. Beregi E. (1982) The significance of lipofuscin in the aging process, especially in neurons, in Neural Aging and Its Implications in Human Neurological Pathology (Terry R. D., Bolis C. L., and Toffano G., eds). pp. 15-21. Raven Press, New York.
6. Bossi S. R., Simpson J. R., and Isacson I. (1993) Age dependence of striatal neuronal death caused by mitochondrial dysfunction. Neuroreport 4, 73-76.
7. Chen T. S., Richie J. P., and Lang C. A. (1989) The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc. Soc. Exp. Biol. Med. 190, 399-402.
8. Corrodi H., Hillard N., and Jonsson G. (1964) Fluorescence methods for the histochemical demonstration of monoamines. 3. Sodium borohydride reduction of the fluorescent compounds as a specificity test. J. Histochem. Cytochem. 12, 582-586.
9. Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative diseases. Science 262, 689-694.
10. De Haan J. B., Newman J. D., and Kola I. (1992) Cu/Zn superoxide dismutase mRNA and enzyme activity, and susceptibility to lipid peroxidation, increases with aging in murine brains. Brain Res. Mol. Brain Res. 13, 179-187.
11. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P., and Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
12. Fahn S. and Cohen G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32, 804-812.
13. Feiten D. L., Felten S. Y., Fuller R. W., Romano T. D., Barry Smalstig E., Wong D. T., and Clemens J. A. (1992) Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged F344 rats. Neurobiol. Aging 13, 339-351.
14. Furness J. B., Heath J. W., and Costa M. (1978) Aqueous aldehyde (FAGLU) methods for the fluorescence histochemical localization of catecholamines and for ultrastructural studies of central nervous tissue. Histochemistry 57, 285-295.
15. Fuxe K. and Jonsson G. (1973) The histochemical fluorescence method for the demonstration of catecholamines. J. Histochem. Cytochem. 21, 293-311.
16. Gerlach M., Ben-Shachar D., Riederer P., and Youdim M. B. H. (1994) Altered brain metabolism of iron as a cause for neurodegenerative disease? J. Neurochem. 63, 793-807.
17. Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
18. Griffith O. W. and Meister A. (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254, 7558-7560.
19. Gupta M., Gupta B. K., Thomas R., Bruemmer V., Sladek J. R. Jr., and Felten D.-L. (1986) Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci. Lett. 70, 326-331.
20. Halliwell B. and Gutteridge J. M. C. (1985) Oxygen radicals and the nervous system. Trends Neurosci. 8, 22-26.
21. Heikkila R. E., Sieber B.-A., Manzino L., and Sonsalla P. K. (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropathol. 10, 171-181.
22. Hirsch E. C. (1992) Why are catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol. 32 (Suppl.), S88-S93.
23. Lee F. Y. F., Allalunis-Turner J., and Siemann D. W. (1987) Depletion of tumor versus normal tissue glutathione by buthionine sulfoximine. Br. J. Cancer 56, 33-38.
24. Lee F. Y. F., Siemann D., Allalunis-Turner J., and Keng P. (1988) Glutathione contents in humans and rodent cells in various phases of the cell cycle. Cancer Res. 48, 3661-3665.
25. Masuoka D. T., Jonsson G., and Finch C. E. (1979) Aging and unusual catecholamine-containing structures in the mouse brain. Brain Res. 169, 335-341.
26. McNeill T. H., Koek L. L., and Haycock J. W. (1984) Age-correlated changes in dopaminergic nigrostriatal perikarya of the C57BL/6NNi mouse. Mech. Ageing Dev. 24, 293-307.
27. Minchinton A. I., Rojas A., Smith K. A., Soranson J. A., Shrieve D. C., Jones N. R., and Bremner J. C. (1984) Glutathione depletion in tissues after administration of buthionine sulphoximine. Int. J. Radiat. Oncol. Biol. Phys. 10, 1261-1264.
28. Mo J. Q., Hom D. G., and Andersen J. K. (1995) Oxidative damage in aged mouse brain correlates with decreases in protective enzymes. Mech. Aging Dev. 81, 73-82.
29. Morgan D. G., May P. C., and Finch C. E. (1987) Dopamine and serotonin systems in human and rodent brain: effects of age and degenerative disease. J. Am. Geriatr. Soc. 35, 334-345.
30. Nandy J. (1971) Properties of neuronal lipofuscin pigment in mice. Acta Neuropathol. (Berl.) 19, 25-32.
31. Perry T. L. and Yong V. W. (1986) Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269-274.
32. Perry T. L., Godin D. V., and Hansen S. (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
33. Pileblad E. and Magnusson T. (1989) Intracerebroventricular administration of L-buthionine sulfoximine: a method for depleting brain glutathione. J. Neurochem. 53, 1878-1882.
34. Pileblad E. and Magnusson T. (1990) Effective depletion of glutathione in rat striatum and substantia nigra by L-buthionine sulfoximine in combination with 2-cyclohexen-1-one. Life Sci. 47, 2333-2342.
35. Reed D. J. and Fariss M. W. (1984) Glutathione depletion and susceptibility. Pharmacol. Rev. 36 (Suppl.), 25S-33S.
36. Ricaurte G. A., DeLanney L. E., Irwin I., and Langston J. W. (1987a) Older dopaminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26, 97-99.
37. Ricaurte G. A., Irwin I., Forno L. S., DeLanney L. E., Langston E., and Langston J. W. (1987b) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res. 403, 43-51.
38. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
39. Slivka A., Spina M. B., Calvin H. I., and Cohen G. (1988) Depletion of brain glutathione in preweanling mice by L-buthionine sulfoximine. J. Neurochem. 50, 1391-1393.
40. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G., and Youdim M. B. H. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205.
41. Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M. B. H. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56, 978-982.
42. Thanislass J., Raveendran M., and Devaraj H. (1995) Buthionine sulfoximine-induced glutathione depletion. Its effect on antioxidants, lipid peroxidation and calcium homeostasis in the lung. Biochem. Pharmacol. 50, 229-234.
43. Yong V. W., Perry T. L., and Krisman A. A. (1986) Depletion of glutathione in brainstem of mice by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant treatment. Neurosci. Lett. 63, 56-60.
44. Youdim M. B. H. and Riederer P. J. (1993) The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J. Neural Transm. 40, 57-67.
45. Zaleska M. M., Nagy K., and Floyd R. A. (1989) Regional lipid peroxidation in rat brain in vitro: possible role of endogenous iron. Neurochem. Res. 10, 397-410.